Moreover, NLRP3 activation in the murine model of NASH increases fibrosis, signifying NLRP3 as a potential target to inhibit or reverse the development of fibrotic NASH [130]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.